A non-proteinogenic amino acid in which the amino group is located on the carbon atom at the position beta to the carboxy group.
ChEBI ID: 33706
| Member | Definition | Role |
|---|---|---|
| 2,3-diaminopropionic acid | A diamino acid that is alanine in which one of the hydrogens of the methyl group is replaced by an amino group. | 3-aminoalanine zwitterion; 3-aminoalanine |
| 3-amino-3-phenylpropionic acid | A beta-amino acid that is beta-alanine substituted at position 3 by a phenyl group. | 3-amino-3-phenylpropanoic acid; 3-ammonio-3-phenylpropanoate |
| 3-aminobutyric acid | A beta-amino acid that is butyric acid which is substituted by an amino group at position 3. | 3-aminobutanoic acid zwitterion; 3-aminobutanoic acid |
| 3-aminoisobutyric acid | A beta-amino-acid that is isobutyric acid in which one of the methyl hydrogens is substituted by an amino group. | 3-aminoisobutanoic acid zwitterion; 3-aminoisobutyric acid |
| beta-alanine | A naturally-occurring beta-amino acid comprising propionic acid with the amino group in the 3-position. | beta-alanine zwitterion; beta-alanine |
| beta-leucine | A beta-amino acid that is pentanoic acid substituted at positions 3 and 4 by amino and methyl groups respectively. | beta-leucine |
| guvacine | A alpha,beta-unsaturated monocarboxylic acid that is nicotinic acid which has been hydrogenated at the 1-2 and 5-6 positions of the pyridine ring. | guvacine |
| nipecotic acid | A piperidinemonocarboxylic acid that is piperidine in which one of the hydrogens at position 3 is substituted by a carboxylic acid group. | nipecotic acid |
| tiagabine | A piperidinemonocarboxylic acid that is (R)-nipecotic acid in which the hydrogen attached to the nitrogen has been replaced by a 1,1-bis(3-methyl-2-thienyl)but-1-en-4-yl group. A GABA reuptake inhibitor, it is used (generally as the hydrochloride salt) for the treatment of epilepsy. | tiagabine |
| Timeframe | Studies, Drugs in This Class (%) | All Drugs % |
|---|---|---|
| pre-1990 | 497 (11.95) | 18.7374 |
| 1990's | 664 (15.97) | 18.2507 |
| 2000's | 811 (19.50) | 29.6817 |
| 2010's | 1,894 (45.55) | 24.3611 |
| 2020's | 292 (7.02) | 2.80 |
| Publication Type | Studies, Drugs in This Class (%) | All Drugs (%) |
|---|---|---|
| Trials | 318 (7.10%) | 5.53% |
| Reviews | 593 (13.23%) | 6.00% |
| Case Studies | 281 (6.27%) | 4.05% |
| Observational | 16 (0.36%) | 0.25% |
| Other | 3,273 (73.04%) | 84.16% |